The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Recruiting

Conditions: Lung Cancer

Interventions: Genetic: comparative genomic hybridization
Genetic: gene expression microarray analysis
Genetic: proteomic profiling analysis
Other: biologic sample preservation procedure
Procedure: nasal brushing
Procedure: Blood draw
Procedure: Urine collection
Procedure: sputum sample
Procedure: fluorescence bronchoscopy with airway biopsy
Procedure: fine needle aspiration of the lung
Procedure: thoracentesis

First Posted Date: 2009-05-12

Last Posted Date: 2023-11-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 4000

Registration Number: NCT00898313

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Completed

Conditions: Lung Cancer

Interventions: Genetic: DNA/RNA sequencing and expression levels
Genetic: Protein expression analysis
Procedure: Lung tumor biopsy
Procedure: Blood sample

First Posted Date: 2009-05-12

Last Posted Date: 2017-07-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 204

Registration Number: NCT00897650

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Recruiting

Conditions: Lung Cancer

Interventions: Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: protein expression analysis
Other: biologic sample preservation procedure
Other: laboratory biomarker analysis
Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry

First Posted Date: 2009-05-12

Last Posted Date: 2024-05-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 4000

Registration Number: NCT00897117

Locations: 🇺🇸
Dan Rudy Cancer Center at Saint Thomas Hospital, Nashville, Tennessee, United States
🇺🇸
Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Terminated

Conditions: Melanoma

First Posted Date: 2009-05-12

Last Posted Date: 2016-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 7

Registration Number: NCT00897312

Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: RAD001
Radiation: whole-brain radiation therapy

First Posted Date: 2009-05-05

Last Posted Date: 2012-03-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 5

Registration Number: NCT00892801

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Sorafenib
Drug: Erlotinb

First Posted Date: 2009-02-06

Last Posted Date: 2014-06-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 37

Registration Number: NCT00837876

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States

and more 3 locations

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2008-10-02

Last Posted Date: 2016-04-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 44

Registration Number: NCT00765245

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Phase 3

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic/Myeloproliferative Neoplasms
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: cyclosporine ophthalmic emulsion
Other: placebo

First Posted Date: 2008-09-18

Last Posted Date: 2017-03-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 164

Registration Number: NCT00755040

Locations: 🇺🇸
Norwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

PET Study in Patients With Non-Hodgkin Lymphoma

Completed

Conditions: Lymphoma

Interventions: Radiation: fluorine 18-fludeoxyglucose positron emission tomography

First Posted Date: 2008-07-10

Last Posted Date: 2013-02-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 55

Registration Number: NCT00712556

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: cisplatin
Drug: everolimus
Drug: paclitaxel

First Posted Date: 2008-05-20

Last Posted Date: 2013-03-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 18

Registration Number: NCT00680758

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Sarah Cannon Cancer Center at Centennial Medical Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy